NHS Greater Glasgow & Clyde Area Drug and Therapeutics Committee
Greater Glasgow and Clyde Medicines
Medicines Update Oncology

New WOSCAN protocols (November 2015)

The following West of Scotland Cancer Network (WOSCAN) protocols have been prepared in response to national guidance and are now available on the WOSCAN intranet site (NHS network access required):

 

Abiraterone acetate with prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated 

- For protocol click here

- The GGC Formulary entry has been updated. Click here

- For relevant SMC advice click here

 

Bosutinib for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options

- For protocol click here

- The GGC Formulary entry has been updated. Click here

- For relevant SMC advice click here

 

Brentuximab vedotin for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option

-  For protocol click here 

-  The GGC Formulary entry has been updated. Click here

-  For relevant SMC advice click here 

 

Dabrafenib monotherapy treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation who have received no prior therapy

- For protocol click here 

- The GGC Formulary entry has been updated. Click here

- For relevant SMC advice click here

 

Nintedanib in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy

 -  For protocol click here

-   The GGC Formulary entry has been updated. Click here                                                   

-   For relevant SMC advice click here

 

Obinutuzumab in combination with chlorambucil for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy

- For protocol click here

- The GGC Formulary entry has been updated. Click here

- For relevant SMC advice click here

 

Ofatumumab in combination with chlorambucil or bendamustine for the treatment of patients with CLL who have not received prior therapy and who are not eligible for fludarabine-based therapy

- For protocol click here

- The GGC Formulary entry has been updated. Click here

- For relevant SMC advice click here

 

Paclitaxel albumin in combination with gemcitabine for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas

 -   For protocol click here 

-    The GGC Formulary entry has been updated. Click here

-    For relevant SMC advice click here 

 

Pemetrexed monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy

 -  For protocol click here

-   The GGC Formulary entry has been updated. Click here 

-   For relevant SMC advice click here 

 

Regorafenib for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib

 - For protocol click here

 - The GGC Formulary entry has been updated. Click here 

-  For relevant SMC advice click here

 

Ruxolitinib for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis

- For protocol click here

- The GGC Formulary entry has been updated. Click here

- For relevant SMC advice click here

 

Sorafenib for the treatment of patients with progressive, locally advanced or metastatic, differentiated thyroid carcinoma, refractory to radioactive iodine

- For protocol click here

- The GGC Formulary entry has been updated. Click here

- For relevant SMC advice click here

 

Subcutaneous trastuzumab for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) and early breast cancer (EBC) in a range of settings

 -  For protocols click here 

-   The GGC Formulary entry has been updated. Click here 

-   For relevant SMC advice click here

 

In addition, the following regionally developed protocols have been approved and are also available on the WOSCAN intranet site.  Please note that these are regional consensus developments and are therefore not the subject of national advice:

 

Cisplatin and capecitabine in squamous cell carcinoma of oesophagus.  For protocol click here.

Zoledronic acid in patients on long term androgen deprivation therapy for prostate cancer. For Bone Health Clinical Management Guideline click here.

Degarelix in patients with cardiovascular risk factors.  For relevant Clinical Management Guideline click here

Docetaxel for androgen dependant metastatic prostate cancer.  For protocol click here

Capecitabine and streptozocin for neuroendocrine tumours (NET).  For protocol click here.